These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Allogeneic transplantation: a therapeutic option for myelofibrosis, chronic myelomonocytic leukemia and Philadelphia-negative/BCR-ABL-negative chronic myelogenous leukemia. Mittal P; Saliba RM; Giralt SA; Shahjahan M; Cohen AI; Karandish S; Onida F; Beran M; Champlin RE; de Lima M Bone Marrow Transplant; 2004 May; 33(10):1005-9. PubMed ID: 15048141 [TBL] [Abstract][Full Text] [Related]
3. Quantitative competitive reverse transcriptase-polymerase chain reaction for BCR-ABL on Philadelphia-negative leukaphereses allows the selection of low-contaminated peripheral blood progenitor cells for autografting in chronic myelogenous leukemia. Corsetti MT; Lerma E; Dejana A; Basta P; Ferrara R; Benvenuto F; Vassallo F; Abate M; Piaggio G; Parodi C; Sessarego M; Li Pira G; Manca F; Carella AM Leukemia; 1999 Jul; 13(7):999-1008. PubMed ID: 10400414 [TBL] [Abstract][Full Text] [Related]
4. Allogeneic hematopoietic stem cell transplantation for the treatment of BCR-ABL1-negative atypical chronic myeloid leukemia and chronic neutrophil leukemia: A retrospective nationwide study in Japan. Itonaga H; Ota S; Ikeda T; Taji H; Amano I; Hasegawa Y; Ichinohe T; Fukuda T; Atsuta Y; Tanizawa A; Kondo T; Miyazaki Y Leuk Res; 2018 Dec; 75():50-57. PubMed ID: 30458320 [TBL] [Abstract][Full Text] [Related]
5. Mobilization/transplantation of Ph1-negative blood progenitor cells in chronic myelogenous leukaemia. Carella AM; Podestà M; Lerma E; Dejana A; Prencipe E; Vassallo F; Crescenti C; Soracco M; Benvenuto F; Chimirri F; Carlier P; Florio G; Valbonesi M; Frassoni F Ann Oncol; 1996; 7 Suppl 2():19-22. PubMed ID: 8805945 [No Abstract] [Full Text] [Related]
6. Allogeneic stem cell transplantation in patients with atypical chronic myeloid leukaemia: a retrospective study from the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplantation. Onida F; de Wreede LC; van Biezen A; Eikema DJ; Byrne JL; Iori AP; Schots R; Jungova A; Schetelig J; Finke J; Veelken H; Johansson JE; Craddock C; Stelljes M; Theobald M; Holler E; Schanz U; Schaap N; Bittenbring J; Olavarria E; Chalandon Y; Kröger N Br J Haematol; 2017 Jun; 177(5):759-765. PubMed ID: 28369779 [TBL] [Abstract][Full Text] [Related]
7. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies. Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713 [TBL] [Abstract][Full Text] [Related]
9. Graft vs autoimmunity following allogeneic non-myeloablative blood stem cell transplantation in a patient with chronic myelogenous leukemia and severe systemic psoriasis and psoriatic polyarthritis. Slavin S; Nagler A; Varadi G; Or R Exp Hematol; 2000 Jul; 28(7):853-7. PubMed ID: 10907647 [TBL] [Abstract][Full Text] [Related]
10. High doses of cyclophosphamide, etoposide and total body irradiation followed by autologous stem cell transplantation in the management of patients with chronic myelogenous leukemia. Kantarjian HM; Talpaz M; Andersson B; Khouri I; Giralt S; Rios MB; Champlin R; Hester J; Deisseroth AB Bone Marrow Transplant; 1994 Jul; 14(1):57-61. PubMed ID: 7951120 [TBL] [Abstract][Full Text] [Related]